References
- Bjorkman L, Dahlgren C, Karlsson A, Brown KL, Bylund J. (2008). Phagocyte-derived reactive oxygen species as suppressors of inflammatory disease. Arthritis Rheum58: 2931–2935.10.1002/art.23941
- Bylund J, Brown KL, Movitz C, Dahlgren C, Karlsson A. (2010). Intracellular generation of superoxide by the phagocyte NADPH oxidase: How, where, and what for? Free Rad Biol Med48: 1834–1845.10.1016/j.freeradbiomed.2010.09.016
- Capsoni F, Sarzi-Puttini P, Atzeni F, Minonzio F, Bonara P, Doria A, Carrabba M. (2005). Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. Arthritis Res Ther7: R250–R255.10.1186/ar1477
- Dahlgren C, Karlsson A. Respiratory burst in human neutrophils. (1999). J Immunol Methods232: 3–14.10.1016/S0022-1759(99)00146-5
- Dahlgren C, Karlsson A, Bylund J. (2007). Measurement of respiratory burst products generated by professional phagocytes. Methods Mol Biol412: 349–363.
- Den Broeder AA, Wanten GJA, Oyen WJG, Naber T, van Riel PLCM, Barrera P. (2003). Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-α monoclonal antibody in patients with rheumatoid arthritis. J Rheumatol30: 232–237.
- Hartmann P, Franzen C, Rubbert A, Rogowski J, Kailus M, Salzberger B. (2005). Blockade of TNF does not alter oxygen burst and phagocytosis of human neutrophils in patients with rheumatoid arthritis. Immunobiology209: 669–679.
- Hultqvist M, Olsson LM, Gelderman KA, Holmdahl R. (2009). The protective role of ROS in autoimmune disease. Trends Immunol30: 201–208.10.1016/j.it.2009.03.00419356981
- Jančinová V, Drábiková K, Nosáľ R, Račková L, Májeková M, Holomáňová D. (2006). The combined luminol/isoluminol chemiluminescence method for differentiating between extracellular and intracellular oxidant production by neutrophils. Redox Rep11: 110–116.10.1179/135100006X11659216805965
- Kolaczkowska E, Kubes P. (2013). Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol13: 159–175.10.1038/nri339923435331
- Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW. (2002). Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol103: 13–21.
- Nakamura M, Nakamura S. (1998). One- and two-electron oxidations of luminol by peroxidase systems. Free Rad Biol Med24: 537–544.
- Rájecký M, Lojek A, Číž M. (2012). Differentiating between intra- and extra-cellular chemiluminescence in diluted whole-blood samples. Int J Lab Hem34: 136–142.10.1111/j.1751-553X.2011.01370.x21834798
- Ristola M, Repo H. (1989). Luminol-enhanced chemiluminescence of whole blood. APMIS97: 503–512.10.1111/j.1699-0463.1989.tb00823.x
- Sedger LM, McDermott MF. (2014). TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future. Cytokine Growth Factor Rev25: 453–472.
- Semerano L, Minichiello E, Bessis N, Boissier MC. (2016). Novel immunotherapeutic avenues for rheumatoid arthritis. Trends Mol Med22: 214–229.10.1016/j.molmed.2016.01.00526875450
- Thieblemont N, Wright HL, Edwards SW, Witko-Sarsat V. (2016). Human neutrophils in auto-immunity. Semin Immunol28: 159–173.10.1016/j.smim.2016.03.00427036091